• Plos One · Jan 2014

    Randomized Controlled Trial Multicenter Study

    Therapeutic effect of Jinzhen oral liquid for hand foot and mouth disease: a randomized, multi-center, double-blind, placebo-controlled trial.

    • Jun Liu, Guo-Liang Zhang, Gui-Qin Huang, Li Li, Chun-Ping Li, Mei Wang, Xiao-Yan Liang, Di Xie, Chang-Ming Yang, Yan Li, Xiu-Rong Sun, Hong-Sen Zhang, Bai-Song Wan, Wei-Hua Zhang, Hao Yu, Ru-Yang Zhang, Ya-Nan Yu, Zhong Wang, and Yong-Yan Wang.
    • Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
    • Plos One. 2014 Jan 1; 9 (4): e94466.

    BackgroundNo specific antiviral agent against hand foot and mouth disease (HFMD) is available for clinical practice today.ObjectiveTo evaluate the efficacy and safety of Jinzhen oral solution in treating uncomplicated HFMD.MethodsIn this randomized, double-blind, placebo-controlled trial, 399 children aged 1 to 7 years with laboratory confirmed HFMD were randomized to receive Jinzhen oral liquid or placebo 3 times daily for 7 days with a 3-day follow-up. The primary outcomes were time to the first disappearance of oral ulcers and vesicles on hand or foot and time to the first normalization of temperature (fever clearance).ResultsThere were 199 children enrolling into the Jinzhen group including 79 with fever and 200 into the placebo group including 93 with fever. Jinzhen reduced the time to the first disappearance of oral ulcers and vesicles on hand or foot to 4.9 days (95% CI, 4.6 to 5.2 days), compared with 5.7 days (95% CI, 5.4 to 6.0 days) in the placebo group (P = 0.0036). The median time of fever clearance was shorter in the 79 children who received Jinzhen (43.41 hrs, 95% CI, 37.05 to 49.76) than that in the 93 children who received placebo (54.92 hrs, 95% CI, 48.16 to 61.68) (P = 0.0161). Moreover, Jinzhen reduced the risk of symptoms by 28.5% compared with placebo (HR, 0.7150, 95% CI, 0.5719 to 0.8940, P = 0.0032). More importantly, treatment failure rate was significantly lower in the Jinzhen group (8.04%) compared with that in the placebo group (15.00%) (P = 0.0434). The incidence of serious adverse events did not differ significantly between the two groups (9 in Jinzhen group vs. 18 in placebo, P = 0.075).ConclusionsChildren with HFMD may benefit from Jinzhen oral liquid treatment as compared with placebo.Trial RegistrationChinese Clinical Trial Registry (http://www.chictr.org/en/) ChiCTR-TRC-10000937.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!

We guarantee your privacy. Your email address will not be shared.